

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


03CO
#4

In re application of

Motoharu SEIKI et al.

Serial No. 09/734,002

Filed December 12, 2000



Docket No. 2000-1617

Group Art Unit 1653

Examiner Not Yet Assigned

NOVEL PROTEIN AND MONOCLONAL
ANTIBODY SPECIFIC THERETO

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

PRELIMINARY REMARKS

Assistant Commissioner for Patents,
Washington, D.C. 20231

Sir:

Responsive to the Notice dated March 15, 2001, Applicants wish to state that the content of the paper and computer readable copies of the Sequence Listing submitted December 12, 2000 are the same and that no new matter has been added.

A copy of the Notice is also attached as required

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Motoharu SEIKI et al.

By: _____

Lee Cheng

Registration No. 40,949

Attorney for Applicants

LC/gtn
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 21, 2001